Adding pegylated interferon to entecavir improves hepatitis B treatment response
Is a simple sofosbuvir plus ribavirin regimen suitable for difficult-to-treat hepatitis C patients?
Hepatitis C patients with cirrhosis respond well to boceprevir or telaprevir with careful monitoring
Brivanib fails to match sorafenib for liver cancer, but tivantinib looks promising
Telaprevir and VX-222 pair well in interferon-free regimen, VX-135 on the horizon
Nucleoside analogues reduce hepatitis B liver cancer risk
Telaprevir twice-daily works as well as every eight hours, safe for hepatitis C patients with cirrhosis
Which patients should be prioritised for new hepatitis C treatments?
Low viral load in hepatitis C treatment: Is a third drug necessary?
Tenofovir safe and effective for long-term hepatitis B treatment with little bone loss
Sofosbuvir and daclatasvir dual regimen cures most people with HCV genotypes 1, 2, or 3
Interferon-free hepatitis C treatment with faldaprevir proves safe and effective in people with cirrhosis
Simeprevir is safe and effective with interferon/ribavirin for hepatitis C patients with cirrhosis
Sofosbuvir demonstrates high response rate in interferon-free combination with ribavirin and GS-5885
94% response rate to HCV treatment without ribavirin or interferon in harder-to-treat
Reducing ribavirin and adding EPO are both good anaemia management strategies for people taking boceprevir
Abbott interferon-free combination 'promising' in harder-to-treat patients with hepatitis C
